KRAS and cholangiocarcinoma: These studies allowed demonstrating the role of Kirsten rat sarcoma viral oncogene homolog (KRAS), tumor protein 53 (TP53), and cyclin-dependent kinase inhibitor 2A (CDKN2A) mutations in the onset and progression of CCA.